文献速递膀胱癌与上尿路尿路上皮癌

国际膀胱癌工作组中危非肌层浸润性膀胱癌分层模型的外部验证

External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model.
PubMed 文献 · Eur Urol Oncol · 2026-06-11

这项多中心回顾性研究纳入2822例中危非肌层浸润性膀胱癌患者,按IBCG模型分为IR-low、IR-intermediate和IR-high三组。3年随访显示复发率分别为12%、38%、77%,进展率分别为1%、3%、7%,Fine-Gray模型证实风险分层与复发和进展显著相关(均p<0.001)。

要点

  • IBCG模型可将中危NMIBC可靠分为3个预后显著不同的组别
  • IR-high组3年复发率77%、进展率7%,风险最高
  • 该外部验证支持将IBCG分层整合进临床实践和指南制定

核心结论

  • IBCG分层模型在最大规模外部验证中可将中危NMIBC可靠分为3个预后显著不同的组别。

研究设计与样本

  • 多中心回顾性分析纳入2005至2025年间接受经尿道膀胱肿瘤电切术的中危NMIBC患者2822例,排除所有高级别肿瘤。

主要发现

  • 2822例患者中IR-low 1143例(41%)、IR-intermediate 1535例(54%)、IR-high 144例(5%)。
  • 3年复发率在IR-low、IR-intermediate、IR-high组分别为12%、38%、77%。
  • 3年分期进展率在IR-low、IR-intermediate、IR-high组分别为1%、3%、7%。
  • Fine-Gray模型证实风险类别越高,复发和进展风险显著增加(均p<0.001)。

关键数值与推荐

  • IBCG模型基于5项临床危险因素将患者分为IR-low(0个)、IR-intermediate(1-2个)和IR-high(≥3个)。

临床怎么用

  • 临床可依据IBCG危险因素数目对中危NMIBC进行分层,识别高复发和进展风险患者以调整随访和治疗强度。

局限性

  • 回顾性设计。
  • 治疗实施存在变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) represents a heterogeneous disease group with variable oncologic outcomes. To address the need for consistent risk stratification, the International Bladder Cancer Group (IBCG) proposed a simplified model incorporating five clinical risk factors. OBJECTIVE: We sought to externally independently validate the IBCG risk stratification model among patients with IR NMIBC. DESIGN, SETTING, PARTICIPANTS: We performed a large multi-center retrospective analysis of patients diagnosed with IR NMIBC and treated with transurethral resection of the bladder between 2005 and 2025. As defined by IBCG guidelines, all high-grade tumors were excluded. Based on the number of IBCG-defined clinical risk factors, patients were stratified into IR-low (0), IR-intermediate (1-2), and IR-high (≥3). Competing-risk analyses assessed recurrence and progression. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcomes were recurrence and progression. Competing-risk analyses were used to evaluate associations between risk groups. RESULTS AND LIMITATIONS: A total of 2822 patients with IR NMIBC were included: 1143 (41%) IR-low, 1535 (54%) IR-intermediate, and 144 (5%) IR-high. At 3 years, we observed stepwise increases in recurrence (12% vs 38% vs 77%) and stage progression (1% vs 3% vs 7%) across the IR-low, IR-intermediate, and IR-high groups. Fine-Gray models confirmed significantly increased hazards of recurrence and progression with higher risk categories (all p<0.001). Limitations include the retrospective design and variability in treatment administration. CONCLUSIONS: We present the largest validation to date of the IBCG stratification model for IR NMIBC. Our findings confirm that patients with IR NMIBC can be reliably classified into 3 distinct prognostic groups with significantly different outcomes. These data provide robust external validation of the IBCG scoring system and support its integration into clinical practice and future guideline development.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Siva J, Jonnalagadda R, Aydogdu C, et al. External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model. Eur Urol Oncol. 2026. PMID: 42276878. doi:10.1016/j.euo.2026.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。